Literature DB >> 32375160

Cannabinoid CB2 receptors mediate the anxiolytic-like effects of monoacylglycerol lipase inhibition in a rat model of predator-induced fear.

Devon Ivy1, Francesca Palese1, Valentina Vozella1, Yannick Fotio1, Aylin Yalcin1, Gina Ramirez1, David Mears2,3, Gary Wynn3, Daniele Piomelli4,5,6.   

Abstract

The endocannabinoid system is a key regulator of the response to psychological stress. Inhibitors of monoacylglycerol lipase (MGL), the enzyme that deactivates the endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG), exert anxiolytic-like effects in rodent models via 2-AG-dependent activation of CB1 cannabinoid receptors. In the present study, we examined whether the MGL inhibitor JZL184 might modulate persistent predator-induced fear in rats, a model that captures features of human post-traumatic stress disorder. Exposure to 2,5-dihydro-2,4,5-trimethylthiazoline (TMT), a volatile chemical that is innately aversive to some rodent species, produced in male rats a long-lasting anxiety-like state that was measured 7 days later in the elevated plus maze test. Systemic administration of JZL184 [4, 8 and 16 mg/kg, intraperitoneal (IP)] 4 h before testing caused dose-dependent inhibition of MGL activity and elevation of 2-AG content in brain tissue. Concomitantly, the inhibitor suppressed TMT-induced fear behaviors with a median effective dose (ED50) of 4 mg/kg. A similar behavioral response was observed with another MGL inhibitor, KML29 (4 and 16 mg/kg, IP). Surprisingly, the effect of JZL184 was prevented by co-administration of the CB2 inverse agonist AM630 (5 mg/kg, IP), but not the CB1 inverse agonist rimonabant (1 mg/kg, IP). Supporting mediation of the response by CB2 receptors, the CB2 agonist JWH133 (0.3, 1 and 3 mg/kg, IP) also produced anxiolytic-like effects in TMT-stressed rats, which were suppressed by AM630. Notably, (i) JWH133 was behaviorally ineffective in animals that had no prior experience with TMT; and (ii) CB2 mRNA levels in rat prefrontal cortex were elevated 7 days after exposure to the aversive odorant. The results suggest that JZL184 attenuates the behavioral consequences of predator stress through a mechanism that requires 2-AG-mediated activation of CB2 receptors, whose transcription may be induced by the stress itself.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32375160      PMCID: PMC7298057          DOI: 10.1038/s41386-020-0696-x

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  42 in total

1.  Modulation of anxiety through blockade of anandamide hydrolysis.

Authors:  Satish Kathuria; Silvana Gaetani; Darren Fegley; Fernando Valiño; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Giovanna La Rana; Antonio Calignano; Arcangela Giustino; Maria Tattoli; Maura Palmery; Vincenzo Cuomo; Daniele Piomelli
Journal:  Nat Med       Date:  2002-12-02       Impact factor: 53.440

Review 2.  The molecular logic of endocannabinoid signalling.

Authors:  Daniele Piomelli
Journal:  Nat Rev Neurosci       Date:  2003-11       Impact factor: 34.870

3.  Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice.

Authors:  Leah M Mayo; Anna Asratian; Johan Lindé; Lovisa Holm; Daniel Nätt; Gaëlle Augier; Niclas Stensson; Haley A Vecchiarelli; Georgia Balsevich; Robert J Aukema; Bijar Ghafouri; Primavera A Spagnolo; Francis S Lee; Matthew N Hill; Markus Heilig
Journal:  Mol Psychiatry       Date:  2018-08-17       Impact factor: 15.992

4.  Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.

Authors:  G Gobbi; F R Bambico; R Mangieri; M Bortolato; P Campolongo; M Solinas; T Cassano; M G Morgese; G Debonnel; A Duranti; A Tontini; G Tarzia; M Mor; V Trezza; S R Goldberg; V Cuomo; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

5.  Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial.

Authors:  Leah M Mayo; Anna Asratian; Johan Lindé; Maria Morena; Roosa Haataja; Valter Hammar; Gaëlle Augier; Matthew N Hill; Markus Heilig
Journal:  Biol Psychiatry       Date:  2019-08-13       Impact factor: 13.382

Review 6.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

7.  Brain monoglyceride lipase participating in endocannabinoid inactivation.

Authors:  T P Dinh; D Carpenter; F M Leslie; T F Freund; I Katona; S L Sensi; S Kathuria; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

8.  Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.

Authors:  Giorgio Tarzia; Andrea Duranti; Andrea Tontini; Giovanni Piersanti; Marco Mor; Silvia Rivara; Pier Vincenzo Plazzi; Chris Park; Satish Kathuria; Daniele Piomelli
Journal:  J Med Chem       Date:  2003-06-05       Impact factor: 7.446

9.  Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress.

Authors:  Marco Bortolato; Regina A Mangieri; Jin Fu; Janet H Kim; Oliver Arguello; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Daniele Piomelli
Journal:  Biol Psychiatry       Date:  2007-05-23       Impact factor: 13.382

Review 10.  Multiple functions of endocannabinoid signaling in the brain.

Authors:  István Katona; Tamás F Freund
Journal:  Annu Rev Neurosci       Date:  2012-04-17       Impact factor: 12.449

View more
  8 in total

Review 1.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

2.  Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice.

Authors:  Amaya Austrich-Olivares; María Salud García-Gutiérrez; Lucía Illescas; Ani Gasparyan; Jorge Manzanares
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

3.  Ratio of Omega-6/Omega-3 Polyunsaturated Fatty Acids Associated With Somatic and Depressive Symptoms in People With Painful Temporomandibular Disorder and Irritable Bowel Syndrome.

Authors:  Anne E Sanders; E Diane Weatherspoon; Brandie M Ehrmann; Paul S Soma; Saame R Shaikh; John S Preisser; Richard Ohrbach; Roger B Fillingim; Gary D Slade
Journal:  J Pain       Date:  2022-04-25       Impact factor: 5.383

4.  Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice.

Authors:  Hai-Ying Zhang; Hui Shen; Ming Gao; Zegang Ma; Briana J Hempel; Guo-Hua Bi; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2021-03-28       Impact factor: 5.250

5.  Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression.

Authors:  Beth M Wiese; Erika Liktor-Busa; Aidan Levine; Sarah A Couture; Spyros P Nikas; Lipin Ji; Yingpeng Liu; Kenneth Mackie; Alexandros Makriyannis; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Cannabis Cannabinoid Res       Date:  2020-11-13

Review 6.  Cannabidiol and Neurodevelopmental Disorders in Children.

Authors:  Keith A Kwan Cheung; Murray D Mitchell; Helen S Heussler
Journal:  Front Psychiatry       Date:  2021-05-21       Impact factor: 4.157

7.  Monoacylglycerol Lipase Inhibition Using JZL184 Attenuates Paw Inflammation and Functional Deficits in a Mouse Model of Inflammatory Arthritis.

Authors:  Sara R Nass; Floyd F Steele; Timothy B Ware; Adam H Libby; Ku-Lung Hsu; Steven G Kinsey
Journal:  Cannabis Cannabinoid Res       Date:  2021-05-25

Review 8.  The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health.

Authors:  Sandra Amatriain-Fernández; Henning Budde; Thomas Gronwald; Carla Quiroga; Cristina Carreón; Gerardo Viana-Torre; Tetsuya Yamamoto; Claudio Imperatori; Sérgio Machado; Eric Murillo-Rodríguez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.